Linvencorvir

CAS No. 1808248-05-6

Linvencorvir( —— )

Catalog No. M35768 CAS No. 1808248-05-6

Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 330 In Stock
5MG 250 In Stock
10MG 359 In Stock
25MG 581 In Stock
50MG 761 In Stock
100MG 1014 In Stock
200MG 1376 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Linvencorvir
  • Note
    Research use only, not for human use.
  • Brief Description
    Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
  • Description
    Linvencorvir is an antiviral agent.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV | Antibiotic
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1808248-05-6
  • Formula Weight
    598.69
  • Molecular Formula
    C29H35FN6O5S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 62.5 mg/mL (104.39 mM; Ultrasonic (<60°C)
  • SMILES
    C(OCC)(=O)C=1[C@@H](NC(=NC1CN2C[C@@]3(N(CC2)C(=O)N(CC(C(O)=O)(C)C)C3)[H])C4=NC=CS4)C5=C(C)C(F)=CC=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021
molnova catalog
related products
  • ?-Thujaplicinol

    ?-Thujaplicinol, a hydroxylated thujaplicinone isolated from western red cedar heartwood, has antiviral activity, inhibits hepatitis B virus replication by blocking viral ribonuclease H activity, and can be used in the study of viral infections.

  • HAP-12

    HAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM.

  • AB-423

    AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM).